EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSBGRG00000003666
Gene Symbol: WEE1
1 Cross references
227 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSBGRG00000020429
Gene Symbol: YES1
1 Cross references
260 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSBGRG00000018236
Gene Symbol: ACHE
1 Cross references
234 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSBGRG00000000336
Gene Symbol: ACVRL1
1 Cross references
358 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSBGRG00000011212
Gene Symbol: ACVR2B
1 Cross references
259 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSBGRG00000026296
Gene Symbol: ADORA1
1 Cross references
275 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSBGRG00000023392
Gene Symbol: ADORA2A
1 Cross references
264 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSBGRG00000024242
Gene Symbol: ADORA2B
1 Cross references
201 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSBGRG00000014023
Gene Symbol: ADA
1 Cross references
219 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSBGRG00000000703
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSBGRG00000017305
Gene Symbol: ADRA1B
1 Cross references
265 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSBGRG00000007807
Gene Symbol: ADRA1D
1 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).